Earnings ·
Ascendis Pharma A/S reported second quarter 2026 financial results with total revenue increasing to €339 million from…
ASNDAscendis Pharma A/S
Ascendis Pharma A/S reported second quarter 2026 financial results with total revenue increasing to €339 million from €158 million in the prior year period, driven by a 105% year-over-year surge in product revenue to €315 million. Product sales included €252 million for YORVIPATH, €55 million for SKYTROFA, and €8 million for YUVIWEL. The company achieved an operating profit of €220 million, significantly improving from a €53 million loss in the same period last year, aided by a one-time cash receipt of €158 million from the sale of a Rare Pediatric Disease Priority Review Voucher. Additionally, Ascendis settled all outstanding $575 million convertible senior notes through conversion and was added to multiple Russell U.S. Indexes following its market capitalization growth. The company operates in the biopharmaceutical industry, developing therapies using its TransCon technology platform for rare endocrine diseases.